ISGEC Heavy Engineering Limited — Q2 FY27 — 5 November 2026

1. Overall Tone of Management

Optimistic, with specific areas of caution. Management reported strong standalone growth, record order books, better-than-guided margins and raised FY27 revenue guidance. Its optimism is supported by current results and order momentum, rather than only distant targets. However, the Philippines ethanol business remains loss-making and difficult to forecast, while commodity and freight costs are pressuring profitability. Management’s revenue-growth guidance also does not fully reconcile with the second-half revenue figures it cited.

2. Key Themes from Management Commentary

Strong standalone execution: Q2 revenue rose 17% and PBT 39%; H1 revenue grew 35% and PBT 24%. Excluding subsidiary-related items, business-operating profit rose 38% in Q2 and 44% in H1.
Record order visibility: Standalone orders in hand were ₹8,757 crore and consolidated orders ₹10,273 crore, both records. H1 standalone order booking was ₹4,844 crore.
Margins above prior expectations: Manufacturing EBIT margin was 13.7%, above the 12%–13% range previously guided. Project EBIT margin was 5.7%, close to the 6% year-end target.
Capacity investment: About ₹502 crore is being invested across manufacturing lines. Facilities are largely on schedule; some new capacity is expected to contribute this year, with most incremental output coming in subsequent years.
Project-business strategy: Management continues shifting toward shorter-duration, technology-led work, and away from long-duration projects with substantial civil construction. It sees lower execution uncertainty and better cash flow as benefits.
Export momentum and risks: Export revenue rose to ₹172 crore in Q2 and ₹557 crore in H1. Management expects exports to remain significant, but notes shipping delays, higher freight and volatile input costs.
Philippines ethanol remains a drag: Cavite Biofuel ran at 65%–70% capacity and recorded a ₹164 crore six-month loss, including interest, depreciation and forex effects. Management expects a seasonal restart in December, but offered no full-year guidance.
Sugar business affected by cane availability: Saraswati Sugar Mills’ sales are lower because of weak cane availability and reduced quotas; management is taking steps to improve supply next season.

3. Q&A Analysis

A. FY27 growth guidance and revenue timing

Core questions: Given 35% H1 revenue growth, is the 15%–17% standalone FY27 growth outlook conservative? When will the large order intake translate into sales?
Response: Management said FY27 H2 revenue assumes ₹3,200–3,300 crore, versus ₹3,000 crore in H2 FY26; revenue from the large H1 order intake will mostly come in the following year. It also described the business moving from roughly ₹5,200 crore to about ₹6,200 crore at current visibility.
Assessment: The explanation supports a stronger second half, but the figures do not cleanly reconcile. ₹3,000 crore H1 plus ₹3,200–3,300 crore H2 implies ₹6,200–6,300 crore for FY27, or roughly 19%–21% growth on FY26 standalone revenue of ₹5,229 crore—not 15%–17%. The “₹5,200 crore to ₹6,200 crore” comment similarly implies about 19% growth. Management did not resolve this discrepancy.

B. Cavite Biofuel: losses, depreciation and operating outlook

Core questions: Why is the Philippines business loss-making, what depreciation should be expected, and can it reach break-even?
Response: Management said quarterly depreciation is now expected at about ₹8–9 crore, following a change in depreciation method supported by an external valuation; the prior-year charge included catch-up depreciation. The ₹60 crore quarterly PBIT loss included ₹41 crore of forex loss. Q3 was expected to remain weak because the plant was under seasonal maintenance, with production restarting in December; management hoped for around 90% utilization in January–March and a small positive EBITDA.
Assessment: Management clarified the loss components but declined to provide FY27 guidance, citing uncertainty around forex and feedstock availability. The hoped-for Q4 utilization is not a firm commitment. This contrasts with earlier, more confident descriptions of the plant as cash-positive or self-sustaining.

C. ISGEC Hitachi Zosen outlook

Core questions: How should investors view FY27 revenue and margins, given a strong order book but concerns about margins?
Response: Management forecast turnover about 7%–8% above last year and profit about 5%–7% higher. The order book was ₹1,161 crore, including about ₹800 crore of export orders.
Assessment: More specific than some other subsidiary commentary, although the answer followed an initial “almost similar” description. The outlook implies growth, but does not directly quantify the margin trajectory.

D. Project margins and order selection

Core questions: Is the recent project margin level sustainable, and what is driving the improvement?
Response: Management said its strategy remains to avoid very long-duration and civil-heavy projects, and to favor shorter-cycle, technology-oriented projects. It reiterated a target of around 6% project margin by year-end.
Assessment: Clear on strategic direction, but it did not promise that the current margin is a new steady-state level. Management emphasized continued improvement rather than giving a longer-term margin target.

E. Manufacturing orders, capex and execution

Core questions: Why is the product share of the order book higher, where are orders coming from, and can the new capacity be executed on time?
Response: Management clarified that the cited 38% product share was consolidated and includes ISGEC Hitachi Zosen. It said expansion work is largely on schedule, with orders across auto, oil and gas, petrochemicals, cement and steel. The ₹502 crore expansion could generate ₹1,200 crore of additional revenue; less than ₹100 crore is expected this year, with most contribution in the following years. Management affirmed the potential for consolidated product revenue of about ₹4,000 crore by FY29.
Assessment: Confident about order execution and demand. The revenue potential is a multi-year capacity outcome, not near-term guidance. Management said it may increase capex, but no additional investment has been approved.

F. Commodity risk, fixed-price orders and project-cycle shift

Core questions: How are margins being protected on largely fixed-price orders, and has the shift to short-cycle projects helped with volatility?
Response: Management said manufacturing bids typically have back-to-back supplier offers, rate contracts and contingencies. Project orders generally have few price-variation clauses. Shorter project cycles reduce uncertainty, improve cash flow and lower customer-credit risk.
Assessment: The risk-management explanation was detailed, but management declined to disclose specific materials-side actions. It acknowledged a small adverse profit impact from recent material-cost increases and higher freight.

G. Other income and product-level disclosure

Management attributed subsidiary-related items to dividends, interest on loans to Singapore and CBPI, forex movements, finance costs on ECB funding, and a ₹17 crore expected-credit-loss provision. It directed analysts to the investor-presentation slide for a fuller breakdown, rather than giving a forward estimate.
Management declined to provide product-wise revenue, saying product mix varies across periods.

H. Sugar and cane availability

Analysts asked whether firmer sugar realizations would help offset lower volumes and whether less cane would be diverted to ethanol.
Management agreed that the business should benefit from higher realizations, but said cane availability remains insufficient, though marginally better than last year. It also noted government restrictions on ethanol production from B-heavy molasses, juice and syrup.

4. Guidance / Outlook

Quantitative guidance
– Standalone FY27 revenue growth: 15%–17%.
– Manufacturing EBIT margin: 12%–13%.
– Projects EBIT margin: Around 6% by year-end.
– Manufacturing capacity investment: About ₹502 crore underway; estimated incremental revenue potential of ₹1,200 crore. Less than ₹100 crore is expected to contribute this year; most contribution is expected from next year onward.
– Product revenue potential: About ₹4,000 crore on a consolidated basis by FY29.
– ISGEC Hitachi Zosen FY27: Turnover up about 7%–8% and profit up about 5%–7% versus last year.
– Cavite Biofuel: No full-year forecast. Management hopes for approximately 90% utilization in January–March and a small positive EBITDA.

Qualitative signals
– Domestic demand and export inquiries remain strong across product and project lines; a weaker rupee is supporting export competitiveness.
– Management expects capacity additions to proceed largely on schedule.
– Middle East tensions have not affected order booking or execution, but have increased costs for some materials and disrupted shipping availability and freight rates. Management expects most incremental costs to be covered by contingency provisions.
– Management said further capex is being evaluated, but has not been finalized.

5. Standout Statements

“The orders will be executed, and they will be executed on time.”
“The objective is to move away from large-scale contracting-type projects to projects that are more technology-oriented and have a shorter cycle time.”
“Most of the revenue will come in the following year.” This tempers the near-term significance of record order intake.
Management said the ₹164 crore six-month Philippines loss included an EBITDA loss that “would have been largely recovered” if the remaining ethanol inventory had been sold during the quarter.
Management’s FY27 revenue-growth explanation—15%–17% guidance alongside a ₹3,200–3,300 crore H2 assumption and a ₹6,200 crore annual run-rate comment—contains an unresolved numerical inconsistency.

6. Red Flags / Positive Signals

Red flags
– Cavite Biofuel remains loss-making, with results sensitive to forex, interest, depreciation, cane availability and ethanol inventory timing; management withheld a full-year forecast.
– FY27 revenue guidance and the accompanying revenue figures do not reconcile clearly.
– Fixed-price contracts and limited price-variation clauses leave some exposure to raw-material and freight volatility.
– Saraswati Sugar Mills continues to face inadequate cane supply.

Positive signals
– Record standalone and consolidated order books, with strong H1 order intake.
– Manufacturing margins exceeded the prior guided range; project margins are near the stated year-end target.
– Standalone net borrowings fell to ₹206 crore from ₹381 crore at March 2026; consolidated net borrowings fell to ₹156 crore from ₹476 crore.
– Capacity additions are largely on schedule, and management sees broad-based domestic and export demand.

7. Historical Comparison & Consistency Analysis

a. Quarter-by-Quarter Tone Evolution

Q2 FY26 — 14 November 2025
– Dominant tone: Neutral
– Major themes this quarter:
– Order book and inquiries were strong; export inquiries had picked up.
– Manufacturing capacity expansion was being planned, including Bartoli and Dahej.
– Philippines sale effort continued, while the plant was preparing to restart for the sugarcane season.
– FGD demand was muted; sugar was described as potentially soft.
– Tone shift vs previous quarter: N/A (baseline)

Q3 FY26 — 10 February 2026
– Dominant tone: Optimistic
– Major themes this quarter:
– Strong order booking and an expanding order book, including export opportunities.
– Multiple manufacturing capacity investments were approved or expanded.
– Management described the Philippines plant as operating well and expected cash break-even in the quarter.
– The shift toward shorter-cycle, private-sector and export orders was emphasized.
– Tone shift vs previous quarter: More Optimistic
– What changed:
– Capex ambition expanded, with manufacturing revenue potential discussed at ₹3,600–3,700 crore.
– Export orders became a more prominent growth lever.
– Management gave a standalone FY27 growth indication of 8%–9%, but did not provide a firm order-book target.

Q4 & FY26 — 29 May 2026
– Dominant tone: Cautious
– Major themes this quarter:
– Management acknowledged FY26 standalone revenue growth of 4.2%, below earlier 7%–8% guidance.
– Core operating PBT was approximately flat after excluding Philippines-related items.
– The Philippines business was reclassified as continuing operations because a sale timeline was uncertain.
– FY27 outlook was raised to 10%–12%, with margin improvement expected in projects.
– Tone shift vs previous quarter: More Cautious
– What changed:
– The call openly acknowledged a material growth miss and weaker underlying operating-profit growth.
– Sale certainty for the Philippines asset weakened; the company remained open to a sale but had no specific buyer at an advanced stage.
– FY27 growth expectations improved versus the prior 8%–9% indication, but were paired with input-cost and geopolitical cautions.

Q2 FY27 — 5 November 2026
– Dominant tone: Optimistic
– Major themes this quarter:
– Strong revenue and PBT growth, record orders, and improved margins.
– Capacity investment and rising export demand were central to the growth narrative.
– The Philippines plant’s losses, forex exposure and seasonal operating outlook remained a substantial drag.
– Cost and logistics pressures were described as manageable, though adverse to profitability.
– Tone shift vs previous quarter: More Optimistic
– What changed:
– Standalone FY27 revenue guidance rose to 15%–17% from 10%–12%, supported by strong H1 performance.
– Management reported better-than-guided manufacturing and project margins and a stronger balance sheet.
– The Philippines discussion shifted from the prior quarter’s “operating well/cash positive” framing toward a quantified six-month loss and no full-year guidance.

Trajectory Summary: The tone moved from neutral in Q2 FY26 to more optimistic in Q3, then turned cautious when FY26 growth missed guidance and the Philippines sale remained uncertain. Q2 FY27 marks a renewed confidence inflection, supported by current growth and margins, but the weak Philippines performance and unresolved revenue-guidance arithmetic qualify the optimism.

b. Tracking Past Commitments vs Outcomes

FY26 revenue growth guidance — ❌ Missed
Past statement: FY26 growth expected at 7%–8% in the Q2 FY26 call; management reaffirmed the guidance in Q3.
Expected: 7%–8% standalone revenue growth.
What happened: FY26 standalone revenue grew 4.2%. Management explicitly acknowledged the shortfall in the Q4 FY26 call.
FY27 standalone growth outlook — ⏳ Revised upward; not yet proven
Past statement: Q3 FY26 indicated 8%–9%; Q4 FY26 raised this to 10%–12%.
What happened: Current guidance is 15%–17%, backed by strong H1 growth. The second-half revenue figures cited by management imply a higher rate still, and were not reconciled.
Cavite Biofuel operational profitability — ❌ Not demonstrated as expected
Past statement: Q2 FY26 management expected revenue of roughly ₹470–480 crore and ₹30–40 crore of profit contribution; it later described the operation as cash-positive/self-sustaining.
What happened: Current H1 FY27 segment loss was ₹164 crore, including interest, depreciation and forex; management also acknowledged an EBITDA loss. The current call gave no full-year earnings guidance. Seasonality and prior catch-up depreciation complicate direct comparison.
Manufacturing capacity expansion — ⏳ In progress
Past statement: Earlier facilities were expected to come online progressively, including Bartoli and Dahej projects.
What happened: Current management said expansions are largely on schedule, with some facilities to be completed progressively this year. Most of the ₹1,200 crore incremental revenue potential is still expected in future years.
Philippines asset sale — ⏳ Delayed
Past statement: Prior calls described ongoing sale efforts and discussions with potential buyers; management said a sale might occur within one to two years.
What happened: The sale did not occur, and the business was reclassified as continuing operations because timing was uncertain. The current call did not give a sale timetable.
FGD retention collections — ⏳ Partially realized; current status unclear
Past statement: Q3 FY26 management expected about ₹250 crore in the March quarter and a further roughly ₹100 crore afterward.
What happened: Q4 FY26 management reported that more than ₹200 crore had been realized and ₹165 crore remained. The current call did not update the outstanding amount.

c. Narrative Shifts

From recovery to growth investment: The narrative has moved from repairing project margins and working capital toward capacity-led manufacturing growth and export expansion.
Philippines: from sale process to ongoing operating exposure: Earlier calls emphasized a planned disposal and successful operations; the latest results foreground continuing losses and no full-year guidance.
Exports have gained prominence: Southeast Asia, Africa and Latin America have become more central to the growth and order-book narrative.
FGD is less prominent: Earlier calls discussed legacy FGD execution, muted demand and retention collections. In the current call, FGD is not a major topic.
Manufacturing mix is emphasized more strongly: The current call highlights a 38% consolidated product share of the order book and an ambition to expand product revenue toward ₹4,000 crore by FY29.

d. Consistency & Credibility Signals

Overall credibility: Medium. Management clearly acknowledged the FY26 revenue miss and has generally explained the Philippines accounting and loss components. However, growth guidance has shifted from 8%–9% to 10%–12% and now 15%–17%, while the current H2 revenue assumptions imply still higher growth. Previous confidence about the Philippines business’s cash generation has also not translated into a clear, sustained earnings outcome. Capacity plans remain in progress rather than delivered.

e. Evolution of Key Themes

Demand and orders — Improving: Order books have risen to record levels, supported by exports and broad-based industrial demand.
Manufacturing margins — Improving: Current 13.7% EBIT margin is above the guided 12%–13% range; management expects the range to hold.
Project margins — Improving: The stated progression from 4.58% in FY26 to 5.7% in Q2 FY27 is consistent with the shorter-cycle, technology-led strategy.
Exports — Improving: Export revenue and export orders have increased; management expects exports to remain significant.
Cavite Biofuel — Deteriorating/uncertain: The plant is operating seasonally, but reported losses remain large and management has withdrawn from giving a full-year outlook.
Input costs and logistics — Deteriorating near term: Steel and other commodities have fluctuated, while shipping delays and freight rates have worsened.

f. Additional Insights

The company’s growth story is increasingly dependent on manufacturing capacity and exports, while much of the new capacity’s revenue contribution lies beyond the current year.
The Philippines business has become harder to treat as a near-term disposal or earnings-recovery story: it is now in continuing operations, still loss-making, and without a clear sale timetable.
Current profitability has improved even as commodity volatility persists, suggesting that supplier arrangements, shorter project cycles and execution may be helping. However, management did not disclose enough detail to determine how durable that protection is.
Strong H1 performance supports a higher FY27 outlook, but the mismatch between formal growth guidance and management’s stated H2 revenue assumptions is a material communication inconsistency.

ISGEC Raises FY27 Growth Outlook as Orders Hit Records